SAB Biotherapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
/ 
Frequently asked questions
To buy SAB Biotherapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for SAB Biotherapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for SAB Biotherapeutics Inc. is SABS:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
SAB Biotherapeutics Inc. has its primary listing on NASDAQ. You can trade SAB Biotherapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, SAB Biotherapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include SAB Biotherapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like SAB Biotherapeutics Inc..